AI Article Synopsis
- The study investigates the intact nephron hypothesis (INH) as a way to determine metformin dosing for patients with chronic kidney disease (CKD), focusing on how the kidney processes drugs.
- Researchers conducted two main analyses: one that looked at how metformin clearance relates to kidney function (eGFR) and another comparing metformin clearance to gentamicin clearance.
- Findings indicate a linear relationship, suggesting that reducing metformin doses based on GFR in CKD patients is appropriate and supported by this research.
Article Abstract
This research explored the intact nephron hypothesis (INH) as a model for metformin dosing in patients with chronic kidney disease (CKD). The INH assumes that glomerular filtration rate (GFR) will account for all kidney drug handling even for drugs eliminated by tubular secretion like metformin. We conducted two studies: (1) a regression analysis to explore the relationship between metformin clearance and eGFR metrics, and (2) a joint population pharmacokinetic analysis to test the relationship between metformin renal clearance and gentamicin clearance. The relationship between metformin renal clearance and eGFR metrics and gentamicin clearance was found to be linear, suggesting that a proportional dose reduction based on GFR in patients with CKD is reasonable.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/bcp.14919 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Study on the mechanism on Yi-guan-jian decoction alleviating cognitive dysfunction in type 2 diabetes mellitus.
J Ethnopharmacol
December 2024
State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, PR China. Electronic address:
Ethnopharmacological Relevance: Yi-guan-jian decoction (YGJ) is a traditional Chinese medicine prescription commonly used for treating syndromes associated with Yin deficiency in the liver and kidney, as well as Qi-obstructed in liver.
Aim Of The Study: YGJ has shown potential alleviating cognitive dysfunction in type 2 diabetes mellitus (T2DM). However, the precise mechanisms are not yet fully understood.
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by hyperglycemia, insulin resistance, and decreased insulin secretion. With its rising global prevalence, effective management strategies are critical to reducing morbidity and mortality. This systematic review compares the efficacy, safety, and long-term outcomes of four major pharmacological treatments for T2DM: sodium-glucose cotransporter-2 (SGLT2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, metformin, and insulin.
View Article and Find Full Text PDFAnti-diabetic therapies on dental implant success in diabetes mellitus: a comprehensive review.
Front Pharmacol
December 2024
Faculty of General Medicine, Yaroslavl State Medical University, Yaroslavl, Russia.
Background And Objective: Dental implant therapy faces challenges in patients with Type 1 and Type 2 Diabetes Mellitus (T1DM and T2DM) due to adverse effects on bone metabolism and immune response. Despite advancements, diabetic patients face higher risks of peri-implantitis and compromised osseointegration. This review assesses the impact of anti-diabetic medications on implant outcomes, offering insights to bridge the gap between animal studies and clinical practice.
View Article and Find Full Text PDFLinsitinib inhibits proliferation and induces apoptosis of both IGF-1R and TSH-R expressing cells.
Front Immunol
December 2024
Molecular Thyroid Research Laboratory, Department of Medicine I, Johannes Gutenberg-University (JGU) Medical Center, Mainz, Germany.
Background: The insulin-like growth factor 1 receptor (IGF-1R) and the thyrotropin receptor (TSH-R) are expressed on orbital cells and thyrocytes. These receptors are targeted in autoimmune-induced thyroid eye disease (TED). Effective therapeutic treatment of TED inhibits activation of the IGF-1R/TSH-R complex.
View Article and Find Full Text PDFRevolutionary drug repositioning: the preventive and therapeutic potential of metformin and other antidiabetic drugs in age-related macular degeneration.
Front Pharmacol
December 2024
Kunshan Hospital of Traditional Chinese Medicine, Suzhou, Jiangsu, China.
Age-related macular degeneration (AMD) is a leading cause of blindness among the elderly worldwide. Anti-vascular endothelial growth factor (anti-VEGF) injections remain the first-line therapy for AMD. However, their high cost and the need for frequent administration pose challenges to long-term adherence, highlighting the need for accessible and cost-effective preventive strategies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!